Acquisitions, Mergers & PartnershipsBioprintingMedical

T&R Biofab and Ethicon bioprinting soft tissue scaffolds for wound treatment

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Bioprinting company T&R Biofab has announced a new collaboration agreement with Ethicon, Inc., a Johnson & Johnson Medical Device Company. The aim of the partnership is to develop a 3D bioprinted soft tissue scaffold for wound treatments, reconstructive surgery and more.

Based in South Korea, T&R Biofab develops and commercializes bioresorbable medical devices and bioinks. The company also pursues research in the area of bioprinted organoids and cell therapeutics. Ethicon, for its part, is a subsidiary of pharmaceutical giant Johnson & Johnson that specializes in wound closure devices and surgical sutures.

Through the collaboration, the companies will leverage their medical expertise to develop soft tissue regeneration and repair products that are differentiated from existing and conventionally manufactured products on the market. The jointly developed products will be produced using T&R Biofab’s 3D platform, which combines polymer, in situ extracellular matrix proteins and 3D bioprinting.

T&R Biofab Ethicon partnership
(Photo: T&R Biofab)

Dr. Wonsoo Yun, CEO of T&R Biofab, commented on the partnership, saying: “We would like to use this opportunity as a stepping stone to generate synergy through the joint R&D agreement with Ethicon, Inc.”

The soft tissue scaffolds developed by the two companies will be intended for use supporting, repairing, elevating or reinforcing anatomical and structural deficiencies. More specifically, the bioprinted tissues could be used for wound treatment applications, such as wound closure and patches; hernia repair; tendon repair; hand surgery; for reinforcing soft tissue in reconstructive or cosmetic surgery; repairing fascial defects; and reconstructing soft tissues.

As per the agreement, Ethicon will be able to “commercially exploit” T&R Biofab’s bioprinting technology with exclusivity. The partnership agreement is being managed by the Johnson & Johnson 3D Printing Center.

Research 2022
Polymer AM Market Opportunities and Trends

741 unique polymer AM companies individually surveyed and studied. Core polymer AM market generated $4.6 billion...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*